All In MedTech

Device Trial Radar · NCT07832929

Gelified Radiopaque Ethanol (Absolute Gel) in Cervical Disc Herniation: an Observational Study in Routine Clinical Practice (GENESIS)

Gelified Radiopaque Ethanol (Absolute Gel) for Cervical Disc Herniation: an Observational Study in Routine Clinical Practice - GENESIS Study

Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Mar 10, 2025

Primary completion

Nov 23, 2026

Study completion Nov 23, 2030

Sponsor

Lead sponsor
Aurel MengriAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 22, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GENESIS is a single-centre, observational, non-interventional, no-profit, investigator-initiated study conducted at Ospedale di Vimercate, ASST Brianza (Italy). The study describes the clinical and functional course of adult patients with cervical disc herniation and chronic discogenic neck pain who receive intradiscal radiopaque gelified ethanol (Absolute Gel), a CE-marked Class III medical device, as part of routine clinical practice and within its approved indications. The study does not assign, introduce or modify any treatment, procedure, medication or follow-up schedule. The decision to treat is taken exclusively by the treating physician according to standard clinical practice. The study only collects clinical and radiological data generated during routine care, both retrospectively (patients already treated) and prospectively (patients treated independently of study participation). Approximately 45 participants are planned. The main descriptive measure is the proportion of participants achieving a reduction of at least 30% in neck pain intensity (Visual Analogue Scale, VAS) at 1 month compared with baseline. Participants are followed up to 48 months after treatment. All analyses are descriptive. The study is not designed to demonstrate efficacy, to support causal inference, or to perform comparisons with other treatments.

Conditions

  • Cervical Disc Herniation
  • Intervertebral Disc Displacement
  • Neck Pain
  • Chronic Pain
  • Radiculopathy

Interventions

  • Absolute Gel (radiopaque gelified ethanol)Device

    CE-marked Class III medical device used within its approved indications as part of standard clinical care. Intradiscal injection of radiopaque gelified ethanol at the cervical level, performed under fluoroscopic guidance through an antero-lateral approach with local anaesthesia, typically 0.3 to 0.4 mL per disc. The study does not assign, impose or modify the treatment, the technique or the peri-procedural management; it records the procedure as performed in routine practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with a reduction of at least 30% in neck pain intensity (VAS) at 1 monthTime frame: Baseline and 1 month (+/-14 days) after treatment
  2. Change from baseline in neck pain intensity (VAS) at 1 monthTime frame: Baseline and 1 month (+/-14 days) after treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ospedale di Vimercate - ASST Brianza

    Vimercate, Monza E Brianza, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.